title: Can determination of gene polymorphism be of practical value in tailoring the treatment of HSCT patients?
authors: 1] L. Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland [2] Lower Silesian Center for Cellular Transplantation with National Bone Marrow Donor Registry, Wroclaw, Poland.
authors: A
authors: A
authors: Lange
authors: 1] L. Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland [2] Lower Silesian Center for Cellular Transplantation with National Bone Marrow Donor Registry, Wroclaw, Poland.
authors: E
authors: E
authors: Jaskula
mesh_terms: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D017209:Apoptosis; D053181:Caspase 8 / Q000235:genetics*; D005260:Female; D019337:Hematologic Neoplasms; D006801:Humans; D008297:Male; D011110:Polymorphism, Genetic; D013601:T-Lymphocytes; D019172:Transplantation Conditioning / Q000009:adverse effects*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D053181:Caspase 8
references: Biol Blood Marrow Transplant. 2009 Oct;15(10):1296-305
references: 19747638
references: Bone Marrow Res. 2012;2012:180391
references: 23119165
references: Biol Blood Marrow Transplant. 2014 Mar;20(3):409-14
references: 24345423
references: Biosci Rep. 2012 Dec;32(6):597-608
references: 22908883
references: Bone Marrow Transplant. 2015 Feb;50(2):237-43
references: 25347010
references: Eur J Immunogenet. 1999 Feb;26(1):1-3
references: 10068907
references: Mutagenesis. 2012 Sep;27(5):559-66
references: 22513478